{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:43:43Z","timestamp":1793040223923,"version":"4.5.0"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1097\/mca.0000000000000438","type":"journal-article","created":{"date-parts":[[2016,10,13]],"date-time":"2016-10-13T12:12:49Z","timestamp":1476360769000},"page":"190-197","source":"Crossref","is-referenced-by-count":23,"title":["Effect of alirocumab dose increase on LDL lowering and lipid goal attainment in patients with dyslipidemia"],"prefix":"10.1097","volume":"28","author":[{"given":"John J.P.","family":"Kastelein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean J.","family":"Kereiakes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Cannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold E.","family":"Bays","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Minini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Veronica","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaman","family":"Maroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Farnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20210204","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jacl.2015.02.003","article-title":"National lipid association recommendations for patient-centered management of dyslipidemia: part 1 \u2013 full report","volume":"9","author":"Jacobson","year":"2015","journal-title":"J Clin Lipidol"},{"key":"R2-4-20210204","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"key":"R3-4-20210204","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"32","author":"Reiner","year":"2011","journal-title":"Eur Heart J"},{"key":"R4-4-20210204","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"R5-4-20210204","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1210\/jc.2015-1520","article-title":"Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I randomized trial","volume":"100","author":"Bays","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"R6-4-20210204","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/eurheartj\/ehv028","article-title":"Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial","volume":"36","author":"Cannon","year":"2015","journal-title":"Eur Heart J"},{"key":"R7-4-20210204","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.atherosclerosis.2015.11.010","article-title":"Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: the ODYSSEY OPTIONS II randomized trial","volume":"244","author":"Farnier","year":"2016","journal-title":"Atherosclerosis"},{"key":"R8-4-20210204","first-page":"2996","article-title":"ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia","volume":"11","author":"Kastelein","year":"2015","journal-title":"Eur Heart J"},{"key":"R9-4-20210204","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.ahj.2015.03.004","article-title":"Efficacy and safety of the PCSK9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study","volume":"169","author":"Kereiakes","year":"2015","journal-title":"Am Heart J"},{"key":"R10-4-20210204","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","article-title":"Efficacy and safety of alirocumab versus ezetimibe in statin-intolerant patients, with a statin-re-challenge arm: the ODYSSEY ALTERNATIVE randomized trial","volume":"9","author":"Moriarty","year":"2015","journal-title":"J Clin Lipidol"},{"key":"R11-4-20210204","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"key":"R14-4-20210204","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.amjcard.2009.08.651","article-title":"Meta-analysis of comparative efficacy of increasing dose of atorvastatin versus rosuvastatin versus simvastatin on lowering levels of atherogenic lipids (from VOYAGER)","volume":"105","author":"Nicholls","year":"2010","journal-title":"Am J Cardiol"},{"key":"R15-4-20210204","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.3390\/nu5041218","article-title":"Dyslipidemia in obesity: mechanisms and potential targets","volume":"5","author":"Klop","year":"2013","journal-title":"Nutrients"}],"container-title":["Coronary Artery Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000000438","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:41:12Z","timestamp":1620960072000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00019501-201705000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/mca.0000000000000438","relation":{},"ISSN":["0954-6928"],"issn-type":[{"value":"0954-6928","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]}}}